Understanding how changes in glucocorticoid receptors contribute to drug resistance in prostate cancer
Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancer
This study is looking at how changes in certain receptors in prostate cancer cells might make them resistant to treatments, and it aims to find new ways to help patients get better results from their therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11072124 on NIH RePORTER |
What this research studies
This research investigates how modifications to glucocorticoid receptors can lead to resistance against treatments for advanced prostate cancer. It focuses on the role of these receptors in evading androgen deprivation therapy and how they can activate alternative survival pathways in cancer cells. By examining the phosphorylation of these receptors and their interaction with the AKT1 protein, the study aims to identify potential therapeutic targets to overcome drug resistance. Patients may benefit from insights that could lead to more effective treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who have developed resistance to standard androgen-targeted therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that effectively combat drug resistance in advanced prostate cancer.
How similar studies have performed: Previous studies have shown promising results in targeting glucocorticoid receptors and AKT pathways in cancer treatment, indicating that this approach may be effective.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Adelaiye-Ogala, Remi — State University of New York at Buffalo
- Study coordinator: Adelaiye-Ogala, Remi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.